Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | HTR1B | P28222 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 2/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 2/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10458625 | 0.85 | KDM4E (0.41) | KDM4ERAB9ASMN1; SMN2HPGDHTR7 | |
| SCHEMBL6768095 | 0.82 | CYP1A2 (0.44) | KDM4ETP53RAB9ASMN1; SMN2HPGD | |
| SCHEMBL8876249 | 0.81 | SMN1; SMN2 (0.42) | KDM4ESMN1; SMN2HPGDHTR7HTR1A | |
| SCHEMBL22400198 | 0.81 | HSD17B10 (0.43) | RAB9ASMN1; SMN2HPGDHTR7SLC6A2 | |
| SCHEMBL4314586 | 0.81 | ALDH1A1 (0.45) | KDM4ERAB9ASMN1; SMN2HPGDHTR7 | |
| SCHEMBL18883696 | 0.81 | CYP1A2 (0.56) | HTR1BHPGDLTA4HCYP1A2CYP2C9 | |
| SCHEMBL9323952 | 0.79 | PTGS2 (0.41) | KDM4ESMN1; SMN2HPGDHTR7HTR1A | |
| SCHEMBL8834938 | 0.79 | KDM4E (0.95) | KDM4EHTR1BTP53MAPK1RAB9A | |
| SCHEMBL31050988 | 0.79 | KDM4E (0.95) | KDM4EHTR1BTP53MAPK1RAB9A | |
| SCHEMBL24495023 | 0.78 | NCF1 (0.44) | KDM4ESMN1; SMN2HPGDHTR7CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109563073-B | For the treatment of para-5-HT1AReceptor-controlled serotonergic disease-modulating compounds | 诺罗利西斯公司 | 2021-12-07 | — | — | CN | disclosed |
| EP-3475268-B9 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | NEUROLIXIS (FR) | 2021-04-21 | — | — | EP | disclosed |
| EP-3475268-B1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | NEUROLIXIS (FR) | 2020-08-19 | — | — | EP | disclosed |
| US-10562853-B2 | Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-HT1A receptors | NEUROLIXIS (FR) | 2020-02-18 | — | — | US | disclosed |
| US-20190194132-A1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | NEUROLIXIS (FR) | 2019-06-27 | — | — | US | disclosed |
| EP-3475268-A1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | Neurolixis (FR) | 2019-05-01 | — | — | EP | disclosed |
| WO-2017220799-A1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | NEUROLIXIS (FR) | 2017-12-28 | — | — | WO | disclosed |
| EP-3260452-A1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | Neurolixis (FR) | 2017-12-27 | — | — | EP | disclosed |
| EP-1888538-B1 | (3,4-DIHYDRO-QUINAZOLIN-2-YL)-(2-ARYLOXY-ETHYL)-AMINES HAVING AN ACTIVITY ON THE 5-HT RECEPTOR | HOFFMANN LA ROCHE (CH) | 2009-11-18 | — | — | EP | disclosed |
| EP-0874805-A1 | PHENYLACETAMIDE DERIVATIVES | Korea Research Institute of Chemical Technology (KR) | 1998-11-04 | — | — | EP | disclosed |
| WO-1997021668-A1 | PHENYLACETAMIDE DERIVATIVES | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1997-06-19 | — | — | WO | disclosed |
| US-4642309-A | CARDIOTONIC AGENTS | BOEHRINGER MANNHEIM GMBH (DE) | 1987-02-10 | — | — | US | disclosed |
| US-4503067-A | HYPOTENSIVE, ANGINA PECTORIS | BOEHRINGER MANNHEIM GMBH (DE) | 1985-03-05 | — | — | US | disclosed |
| US-4468520-A | BETA-BLOCKERS | BOEHRINGER MANNHEIM GMBH (DE) | 1984-08-28 | — | — | US | disclosed |
| EP-0004920-B1 | DERIVATIVES OF CARBAZOLYL-4-OXYPROPANOLAMINE, METHODS FOR THEIR PREPARATION AND MEDICINES CONTAINING THEM | Roche Diagnostics GmbH (DE) | 1981-08-05 | — | — | EP | disclosed |
| EP-0004920-A1 | Derivatives of carbazolyl-4-oxypropanolamine, methods for their preparation and medicines containing them | Roche Diagnostics GmbH (DE) | 1979-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562853-B2 | Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-HT1A receptors | HTR5A, HTR1A, HTR1E | KDM4E 2557/4885HTR1B 12/4885TP53 4555/4885 |
| US-20190194132-A1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | HTR5A, HTR1A, HTR1E | KDM4E 2557/4885HTR1B 12/4885TP53 4555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.